The Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Nasopharyngeal Carcinoma

Inclusion Criteria: * Pathologically confirmed differentiated non-keratinizing carcinoma and undifferentiated non-keratinizing carcinoma * The stage is Ⅲ-ⅣA (UICC 8th edition) * Initial treatment patients without anti-tumor therapy * No history of other malignant tumors * Male or female, aged 18\~70 years old * Sufficient liver and kidney function: total bilirubin ≤ upper limit of normal (ULN); AST and ALT ≤ 2.5 times ULN; alkaline phosphatase ≤ 5 times ULN; creatinine clearance ≥ 80 mL/min * Sufficient blood function: neutrophil count (ANC) ≥2×109/L, platelet count ≥100×109/L and hemoglobin ≥9 g/dL * No serious heart, lung, liver, kidney and other important organ dysfunction * Karnofsky score ≥70 points * No autoimmune diseases * Sign informed consent Exclusion Criteria: * Has performed anti-tumor treatment, including chemotherapy, radiotherapy, and surgery * Discovery of distant metastases before treatment * Receive live attenuated vaccine within 4 weeks before enrollment or plan to receive live attenuated vaccine during the study period * Active, known or suspected autoimmune diseases * Known history of primary immunodeficiency * Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation * Women who are pregnant or breastfeeding * Disagree to sign the informed consent form * Patients who cannot cooperate with regular follow-up due to psychological, social, family and geographic reasons * Simultaneously accept experimental treatment of other clinical research (in the treatment period of clinical research) * Known allergic to possible chemotherapy drugs * Accompanied by serious uncontrollable infections or medical diseases * Major organ dysfunction, such as decompensated heart, lung, kidney, and liver failure, unable to tolerate radiotherapy and chemotherapy * Laboratory examination: total bilirubin\>upper limit of normal (ULN); AST and/or ALT\>1.5 times ULN and accompanied by alkaline phosphatase\>2.5 times ULN